β-Thalassemia: The Lebanese experience

Clinical and Laboratory Haematology

Volumn 28, Issue 4, 2006, Pages 217-227

  Inati, A ^a,b   Zeineh, N ^c   Isma'eel, H ^c   Koussa, S ^a   Gharzuddine, W ^a,c   Taher, A ^a,c  

^a Chronic Care Center Hazmieh   (Lebanon)

^b Nini Hospital   (Lebanon)

^c AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

Thalassemia; Complications; Genetics; Lebanon; Treatment

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CARNITINE; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; ERYTHROPOIETIN; HYDROXYUREA; PEGINTERFERON ALPHA2A; RIBAVIRIN;

ALLOGENIC BONE MARROW TRANSPLANTATION; BETA THALASSEMIA; CAUSE OF DEATH; CHOLECYSTECTOMY; CLINICAL FEATURE; CLINICAL TRIAL; CONSANGUINITY; DEMOGRAPHY; DRUG EFFICACY; DRUG TOLERABILITY; ENDOCRINE DISEASE; ERYTHROCYTE CONCENTRATE; ERYTHROCYTE TRANSFUSION; EXTRAMEDULLARY HEMATOPOIESIS; FERRITIN BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; GENE MUTATION; GENETIC COUNSELING; GENOTYPE; HEALTH EDUCATION; HEART ARRHYTHMIA; HEART DISEASE; HEART FAILURE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOGONADISM; INFECTION; IRON CHELATION; IRON OVERLOAD; LEBANON; LEG ULCER; MEDICAL EXAMINATION; MORTALITY; NAUSEA; NEUTROPENIA; OSTEOPOROSIS; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; PSYCHOTHERAPY; PULMONARY HYPERTENSION; RASH; REVIEW; SCREENING; SPLENECTOMY; THALASSEMIA INTERMEDIA; THALASSEMIA MAJOR; THROMBOSIS;

ADOLESCENT; ADULT; BETA-THALASSEMIA; CHILD; CHILD, PRESCHOOL; ERYTHROCYTE TRANSFUSION; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; LEBANON; MALE; MIDDLE AGED;

EID: 33746383249     PISSN: 01419854     EISSN: 13652257     Source Type: Journal    
DOI: 10.1111/j.1365-2257.2006.00792.x     Document Type: Review

References (44)

1. Al-Momen A.K. (1991) Recombinant human erythropoietin induced rapid healing of a chronic leg ulcer in a patient with sickle cell disease. Acta Haematologica 86, 46-48.
2. Aldouri M.A., Wonke B., Hoffbrand A.V., Flynn D.M., Ward S.E., Agnew J.E. & Hilson A.J. (1990) High incidence of cardiomyopathy in beta-thalassemia patients receiving regular transfusion and iron chelation: reversal by intensified chelation. Acta Haematologica 84, 113-117.
3. Borgna-Pignatti C., Rugolotto S., De Stefano P., Zhao H., Cappellini M.D., Del Vecchio G.C., Romeo M.A., Forni G.L., Gamberini M.R., Ghilardi R., Piga A. & Cnaan A. (2004) Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 89, 1187-1193.
4. Cabannes R., Taleb N., Ghorra F. & Schmitt-Beurrier A. (1965) Etude dea Types Hemoglobiniques dans la Population du Liban. Nouvelle Revue Francaise D'Hematologie 5, 851-856.
5. Camaschella C. & Cappellini M.D. (1995) Thalassemia intermedia. Haematologica 80, 58-68.
6. Cappellini M.D., Robbiolo L., Bottasso B.M., Coppola R., Fiorelli G. & Mannucci A.P. (2000) Venous thromboembolism and hypercoagulability in splenectomized patients with thalassaemia intermedia. British Journal of Haematology 111, 467-473.
7. Chehab F.F., Der Kaloustian V., Khouri F.P., Deeb S.S. & Kan Y.W. (1987) The molecular basis of beta-thalassemia in Lebanon: application to prenatal diagnosis. Blood 69, 1141-1145.
8. Chehal A., Aoun E., Koussa S., Skoury H., Koussa S. & Taher A. (2003) Hypertransfusion: a successful method of treatment in thalassemia intermedia patients with spinal cord compression secondary to extramedullary hematopoiesis. Spine 28, E245-249.
9. Cohen A.R., Galanello R., Pennell D.J., Cunningham M.J. & Vichinsky E. (2004) Thalassemia. Hematology (American Society of Hematology. Education Program) 1, 14-34.
10. Der Kaloustian V.M., Naffah J. & Loiselet J. (1980) Genetic diseases in Lebanon. American Journal of Medical Genetics 7, 187-205.
11. El-Beshlawy A., Ragab L., Fattah A.A., Ibrahim I.Y., Hamdy M., Makhlouf A., Aoun E., Hoffbrand V. & Taher A. (2004) Improvement of cardiac function in thalassemia major treated with L-carnitine. Acta Haematologica 111, 143-148.
12. Eldor A. & Rachmilewitz E.A. (2002) The hypercoagulable state in thalassemia. Blood 99, 36-43.
13. Franzoni F., Galetta F., Di Muro C., Buti G., Pentimone F. & Santoro G. (2004) Heart rate variability and ventricular late potentials in beta-thalassemia major. Haematologica 89, 233-234.
14. Gharzuddine W.S., Kazma H.K., Nuwayhid I.A., Bitar F.F., Koussa S.F., Moukarbel G.V. & Taher A.T. (2002) Doppler characterization of left ventricular diastolic function in beta-thalassaemia major. Evidence for an early stage of impaired relaxation. European Journal of Echocardiography 3, 47-51.
15. Gimmon Z., Wexler M.R. & Rachmilewitz E.A. (1982) Juvenile leg ulceration in beta-thalassemia major and intermedia. Plastic and Reconstructive Surgery 69, 320-325.
16. Hoedemaekers R. & ten Have H. (1998) Geneticization: the Cyprus paradigm. Journal of Medicine and Philosophy 23, 274-287.
17. Inati A., Taher A., Ghorra S., Koussa S., Taha M., Aoun E. & Sharara A.I. (2005) Efficacy and tolerability of peginterferon alpha-2a with or without ribavirin in thalassaemia major patients with chronic hepatitis C virus infection. British Journal of Haematology 130, 644-646.
18. Isma'eel H., Taher A., Shamseddeen W., Alam S., Gharzuddine W., Koussa S., Abdallah M. & Khoury M. (2005a) The Incidence of Ventricular Late Potentials among Thalassemia Patients, 7 years Follow up Study. 8th Cooley's Anemia Symposium, New York Academy of Science (abstract).
19. Isma'eel H., Shamseddeen W., Taher A., Zeineh N., Abdallah M.S., Inati A., Alam S. & Gharzuddin W. (2005b) Cardiac Dysfunction in Thalassemia Major versus Intermedia in Lebanon. 10th International Conference for Thalassaemia and Haemoglobinopathies & 12th International TIF Conference (abstract).
20. Karimi M., Darzi H. & Yavarian M. (2005) Hematologic and clinical responses of thalassemia intermedia patients to hydroxyurea during 6 years of therapy in Iran. Journal of Pediatric Hematology/Oncology 27, 380-385.
21. Khouri F.P., Chehab F.F., Deeb S.S., Habbal Z.M. & Muallem H.E. (1986) Genetic studies in a selected group of Lebanese β-thalassemic patients. Lebanon Medical Journal 36 (Suppl. 2), 69-71.
22. Manfre L., Giarratano E., Maggio A., Banco A., Vaccaro G. & Lagalla R. (1999) MR imaging of the brain: findings in asymptomatic patients with thalassemia intermedia and sickle cell-thalassemia disease. American Journal of Roentgenology 173, 1477-1480.
23. Miskin H., Yaniv I., Berant M., Hershko C. & Tamary H. (2003) Reversal of cardiac complications in thalassemia major by long-term intermittent daily intensive iron chelation. European Journal of Haematology 70, 398-403.
24. Mourad F.H., Hoffbrand A.V., Sheikh-Taha M., Koussa S., Khoriaty A.I. & Taher A. (2003) Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients. British Journal of Haematology 121, 187-189.
25. Nisbet-Brown E., Olivieri N.F., Giardina P.J., Grady R.W., Neufeld E.J., Sechaud R., Krebs-Brown A.J., Anderson J.R., Alberti D., Sizer K.C. & Nathan D.G. (2003) Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 361, 1597-1602.
26. Olivieri N. (1999) The β-thalassemias. New England Journal of Medicine 341, 99-109.
27. Olivieri N.F. & Brittenham G.M. (1997) Iron-chelating therapy and the treatment of thalassemia. Blood 89, 739-761.
28. Olivieri N.F., Nathan D.G., MacMillan J.H., Wayne A.S., Liu P.P., McGee A., Martin M., Koren G. & Cohen A.R. (1994) Survival in medically treated patients with homozygous beta-thalassemia. New England Journal of Medicine 331, 574-578.
29. Olivieri N.F., Brittenham G.M., McLaren C.E., Templeton D.M., Cameron R.G., McClelland R.A., Burt A.D. & Fleming K.A. (1998) Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. New England Journal of Medicine 339, 417-423.
30. Qatanani M., Taher A., Koussa S., Naaman R., Fisher C., Rugless M., Old J. & Zahed L. (2000) Beta-thalassaemia intermedia in Lebanon. European Journal of Haematology 64, 237-244.
31. Ramia S., Koussa S., Taher A., Harald S., Klayme S., Sarkis D. & Naman R. (2002) Hepatitis-C-virus genotypes and hepatitis-G-virus infection in Lebanese thalassaemics. Annals of Tropical Medicine and Parasitology 96, 197-202.
32. Schrier S.L. (1997) Pathobiology of thalassemic erythrocytes. Current Opinion in Hematology 4, 75-78.
33. Shahid M. (1971) Les Thalassemies Alpha. The Lebanese Medical Journal 24, 571-583.
34. Sharara A.I., Hunt C.M. & Hamilton J.D. (1996) Hepatitis C. Annals of Internal Medicine 125, 658-668.
35. Taher A., Abou-Mourad Y., Abchee A., Zalouaa P. & Shamseddine A. (2002) Pulmonary thromboembolism in beta-thalassemia intermedia: are we aware of this complication? Hemoglobin 26, 107-112.
36. Taher A., Aoun E., Sharara A.I., Mourad F., Gharzuddine W., Koussa S., Inati A., Dhillon A.P. & Hoffbrand A.V. (2004) Five-year trial of deferiprone chelation therapy in thalassaemia major patients. Acta Haematologica 112, 179-183.
37. Taher A., Sheikh Taha M., Sharara A., Inati A., Koussa S., Ellis G., Dhillon A.P. & Hoffbrand A.V. (2005) Safety and effectiveness of 100 mg/kg/day deferiprone in patients with thalassemia major: a two year study. Acta Haematologica (in press).
38. Voskaridou E., Douskou M., Terpos E., Papassotiriou I., Stamoulakatou A., Ourailidis A., Loutradi A. & Loukopoulos D. (2004) Magnetic resonance imaging in the evaluation of iron overload in patients with beta thalassaemia and sickle cell disease. British Journal of Haematology 126, 736-742.
39. Wood J.C., Enriquez C., Ghugre N., Tyzka J.M., Carson S. & Nelson M.D. (2005) Coates TD. MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. Blood 106, 1460-1465 (Epub April 28, 2005).
40. Yazigi A., Maalouf G., Inati-Khoriati A., Tamim H. & Saab C. (2002) Bone mineral density in beta-thalassemic Lebanese children. Journal of Musculoskeletal & Neuronal Interactions 2, 463-468.
41. Zahed L. (2001) The spectrum of β-thalassemia mutations in the Arab populations. Journal of Biomedicine & Biotechnology 1, 129-132.
42. Zahed L., Talhouk R., Saleh M., Abou-Jaoudeh R., Fisher C. & Old J. (1997) The spectrum of beta-thalassaemia mutations in the Lebanon. Human Heredity 47, 241-249.
43. Zahed L., Qatanani M., Nabulsi M. & Taher A. (2000) Beta-thalassemia mutations and haplotype analysis in Lebanon. Hemoglobin 24, 269-276.
44. Zahed L., Mourad F.H., Alameddine R., Aoun S., Koussa S. & Taher A. (2002) Effect of oral iron chelation therapy with deferiprone (L1) on the psychosocial status of thalassaemia patients. Haematologia 31, 333-339.